eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Cardiology

Single Ventricle: Follow-up

Author: Alvin J Chin, MD, Professor of Pediatrics, Division of Cardiology, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine
Contributor Information and Disclosures

Updated: Jul 15, 2009

Follow-up

Further Inpatient Care

  • Admit patients with single ventricles for testing and surgical intervention.

Further Outpatient Care

  • Following each stage of surgical reconstruction, echocardiographic and Doppler evaluation of hemodynamic adequacy should be performed.
  • After the Fontan operation, monitor for hepatic and biliary dysfunction (ie, measure prothrombin time [PT], gammaglutamyltranspeptidase [GGT], and factor VIII),22 supraventricular arrhythmias (Holter monitoring), short stature, and protein-losing enteropathy (monitor total protein and albumin levels). If possible, perform morphologic assessment of the systemic and pulmonary venous pathways and the pulmonary artery architecture, as well as measurement of cardiac index, using MRI or cardiac catheterization.
  • Should effusive complications, which are common in the early period after a Fontan procedure, recur months or years later, a comprehensive search for a surgically correctable cause should be undertaken. Examples of such correctable etiologies are late-onset pulmonary venous obstruction and thrombosis of the left pulmonary artery.
  • Only after mechanical obstructions are ruled out should a classic protein-losing enteropathy workup be initiated.

Inpatient & Outpatient Medications

  • The medical treatment of postoperative patients with supraventricular arrhythmias is frequently complex because many patients who have undergone a Fontan operation have sinus node dysfunction and can only be safely administered antiarrhythmic agents if a pacemaker is placed first. Surgical therapy for atrial tachyarrhythmias appears to be preferred over medical therapy.
  • Various "maintenance drug regimens" are empirically used for patients who have undergone a Fontan operation. These include the following:
    • No medications
    • Furosemide
    • Spironolactone
    • ACE inhibitor
    • Sildenafil
    • Digoxin
    • Warfarin (for the first 3 mo after fenestrated Fontan)
    • Combinations of the above medications

Transfer

  • Transfer may be required for further diagnostic evaluation and surgical intervention.

Complications

  • Pleural effusions, pericardial effusions, ascites
    • Long considered the most agonizing early postoperative complication after completion Fontan, thoracic and abdominal effusions often persisted for weeks and frequently impaired cardiac output. Before the early 1990s, these complications threatened to preclude the application of Fontan's principle to the vast majority of patients with single ventricle.
    • Although the molecular and cellular basis of this complication remains a mystery, surgeons have begun using various less-than-complete Fontan operations as their final stage.23 The partial hepatic vein exclusion variation used by Lecompte and then by Norwood has largely been abandoned because more than 80% of patients developed intrahepatic venous collaterals that resulted in increasing right-to-left shunts.
    • Hence, the less-than-complete Fontan operation most widely used since the late 1990s is the fenestrated Fontan operation proposed by Laks. Effusive complications are greatly reduced following the fenestrated Fontan (lateral tunnel or extracardiac conduit). However, arterial oxygen saturation is usually in the high 80s or low 90s, rather than the mid 90s seen after nonfenestrated Fontan.
  • Atrial tachyarrhythmias
    • This is the most prevalent of the numerous late complications following the various modifications of the Fontan operation and may be the heralding sign of hemodynamic deterioration. The basis for this complication is probably multifactorial,24 and its treatment can be complex because of the frequent coexistence of sinus node dysfunction. Surgical therapy appears to be superior to medical therapy.25
    • Current hypotheses for the etiology of the sinus node dysfunction center on surgical trauma to portions of the sinus node region or its blood supply.
    • As an alternative to the hemi-Fontan operation, use of the so-called bidirectional Glenn operation, followed subsequently by extracardiac conduit26 (rather than the lateral tunnel) placement, has failed to reduce the frequency of sinus node dysfunction. This may be because the demarcation of the sinus node region is not macroscopically evident; thus, attempts to avoid it (such as the bidirectional Glenn) may have been unsuccessful.
    • Because the onset of atrial tachyarrhythmia episodes is frequently preceded, if not invariably preceded, by months or years of atrial bradycardia, prophylactic atrial pacing may possibly postpone the emergence of these arrhythmias. Because of the technical challenges of atrial pacing in infants, this proposal has not yet been the subject of a randomized clinical trial.
  • Hepatic and biliary dysfunction22,27
    • Liver dysfunction may actually be the underlying etiology for several of the complications listed below (eg, thromboembolism, varices and other venous-to-venous collaterals, thrombocytopenia)
    • Biliary sludge is the most common finding on gallbladder ultrasonography.
    • Elevated factor VIII, prolonged PT, and elevated GGT are the most sensitive indicators. 
  • Thromboembolism
    • Venous, but not arterial, thrombosis occurs in nearly 10% of survivors of the fenestrated Fontan operation. The cause of this complication is unknown. Sites can include the pulmonary arteries and the cerebral veins.28 Subnormal cardiac output, subnormal intracardiac pulsatility of blood flow, and altered hepatic production of components of endogenous thrombolytic pathways have all been proposed as possible etiologies. Hepatic dysfunction, as measured by prothrombin time and galactose elimination half-life, is the rule.
    • Thrombi have been observed in both the pulmonary venous side of the "lateral tunnel" baffle and the systemic venous side. The presence of a fenestration allows thrombi in the systemic venous circulation to gain access to the systemic arterial circulation.
    • Aspirin is often prescribed as prophylaxis for venous thrombosis following fenestrated Fontan, but it appears to be ineffective in this setting. Warfarin and Lovenox have not gained wide acceptance for prophylaxis in children with Fontan circulation.
  • Protein-losing enteropathy
    • Manifesting as diarrhea, poor appetite, or sometimes simply as growth failure, protein-losing enteropathy occurs in at least 10% of long-term survivors of nonfenestrated Fontan procedures.
    • The cause of this usually devastating complication is unknown. For those with little or no fenestration, fenestration creation (or dilation and stenting) appears to be the most consistently successful palliation, with the improvement sometimes lasting longer than a decade. Atrial pacing has succeeded in at least 2 cases.29 Other proposed remedies, including steroids and heparin, have succeeded in individual cases but have more numerous adverse effects such as osteopenia. Reduction of both CD4+ and CD8+ T lymphocytes is observed; disproportionate reduction of the CD4+ subset results in a reversal of the CD4+/CD8+ ratio. Immunoglobulin G (IgG) levels and, to a lesser extent, immunoglobulin A (IgA) levels are diminished.30
    • Not observed in the pre-1980 era (when Fontan-type operations were rarely performed), protein-losing enteropathy is thus a result of surgically created cavopulmonary/atriopulmonary circulatory arrangements and is not merely a result of being born with a single ventricle heart.
  • Persistent discrete or long-segment narrowing of the left pulmonary artery
    • In the program of staged surgery to reach a fenestrated Fontan, distortions of the left pulmonary artery are frequently difficult to entirely abolish, even at the time of the final stage.
    • The importance of identifying cases of Fontan-to-one-lung circulation31 lies in their vulnerability to the hemodynamic consequences of ipsilateral pulmonary insults. Moreover, 50% of patients with Fontan-to-one-lung circulation develop protein-losing enteropathy, arguing strongly that protein-losing enteropathy is a sequela of Fontan hemodynamics.32
  • Formation of venous collaterals and varices
    • Patients with single ventricle and the coexistence of interrupted inferior vena cava still have hepatic venous blood that drains to the pulmonary venous side of the circulation after a Kawashima variation of the Fontan procedure.
    • Collaterals can occasionally form, allowing venous blood from the upper part of the body to eventually reach the pulmonary venous side of the circulation in this subset of patients with single ventricle, as well as in others.
    • The increased right-to-left shunt can be identified by monitoring either pulse oximetry or hemoglobin levels. 
    • Bronchial wall varices have been observed, possibly due to high superior vena cava pressure.
    • Esophageal varices occur in patients with hepatic dysfunction and portal hypertension.
  • Low exercise capacity33
    • Although individual exceptions have been observed, the exercise capacity of patients who survive the Fontan procedure, even those with fenestrated variants, is subnormal.
    • The resting cardiac index is about 70-80% of normal. Disadvantageous ejection efficiency is present, combined with elevated pulsatile and nonpulsatile components of ventricular afterload.5
  • Short stature
    • This is observed in patients who survive the Fontan operation even in the absence of documented protein-losing enteropathy.
    • The molecular and cellular basis of this complication is unknown; however, low bone-specific alkaline phosphatase appears to increase when cardiac index is augmented. This suggests that reduced osteoblastic function from subnormal bone perfusion may be the culprit.17
    • Whether exogenous growth hormone ameliorates the subnormal growth (but with acceptable incidence of adverse effects) is not known.
  • Formation of pulmonary arteriovenous malformations
    • This complication of the hemi-Fontan operation and its variants appears to largely resolve after the performance of a less-than-complete Fontan operation (of the lateral tunnel, extracardiac conduit, or hepatic vein exclusion varieties).
    • Contrast echocardiography appears to be a highly sensitive method of identifying pulmonary arteriovenous malformations.34
  • Plastic bronchitis35
    • This is characterized by the development of mucinous bronchial casts.
    • Palliation by fenestration creation has been reported.36
  • Formation of systemic-to-pulmonary arterial collaterals
    • Systemic artery-to-pulmonary artery collaterals can carry as much as 40% of the total ventricular output.
    • Whether this is due to the arterial desaturation caused by the fenestration is not yet known.37
  • Thrombocytopenia38 : Whether this is due to deficient thrombopoietin, which is provided by the liver as well as by the kidney, is not yet known.39

Prognosis

  • More than one half of patients should survive 20 years. Patients with even moderate atrioventricular valve regurgitation have a demonstrably poorer outcome.

Patient Education

  • Because the outcome of various modifications of Fontan operation includes a monotonically increasing prevalence of serious sequelae, discussion with families about prognoses are necessarily lengthy.
  • If the initial identification of single ventricle is made in utero, then the possibility of pregnancy termination may also be introduced to family members.
  • Finally, the family should confront the possibility that cardiac transplantation may eventually be needed, even if the staged approach to achieve a fenestrated Fontan is the initial strategy adopted.

Miscellaneous

Medicolegal Pitfalls

  • Failure to recognize symptoms and signs of coexistent arch obstruction
  • Failure to recognize inadequately relieved subaortic stenosis, aortic stenosis, or both

Special Concerns

  • Although treatments for single ventricle (which, as stated earlier in this article, does not include the entity of hypoplastic left heart syndrome) have been refined over the last 30 years, they have not convincingly improved upon the limited palliations offered before 1971. Because of this, extra caution is advised in the initial discussions with the family.
    • Unlike hypoplastic left heart syndrome, in which the staged approach to reach a cavopulmonary circulation is clearly superior to performing only the first stage (Norwood procedure), the vast majority of patients with single ventricle have a morphologic left ventricle (LV), do not present in extremis, and are relatively stable over many years once initial palliation, including a systemic–to–pulmonary arterial shunt, is completed and a pulmonary/systemic flow ratio of between 1.5 and 2.0 is achieved.
    • Whether the cavopulmonary circulation matches or surpasses this quality of life over a 30-year period is still an open question.40 The long-term effect of a mean systemic venous pressure greater than 10 mm Hg is unknown in the pediatric population.
 


More on Single Ventricle

Overview: Single Ventricle
Differential Diagnoses & Workup: Single Ventricle
Treatment & Medication: Single Ventricle
Follow-up: Single Ventricle
Multimedia: Single Ventricle
References

References

  1. Fontan F, Mounicot FB, Baudet E, et al. ["Correction" of tricuspid atresia. 2 cases "corrected" using a new surgical technic]. Ann Chir Thorac Cardiovasc. Jan 1971;10(1):39-47. [Medline].

  2. Bull K. The Fontan procedure: lessons from the past. Heart. Mar 1998;79(3):213-4. [Medline].

  3. de Zelicourt DA, Pekkan K, Wills L, et al. In vitro flow analysis of a patient-specific intraatrial total cavopulmonaryconnection. Ann Thorac Surg. Jun 2005;79(6):2094-102. [Medline].

  4. Earing MG, Cetta F, Driscoll DJ, Mair DD, Hodge DO, Dearani JA. Long-term results of the Fontan operation for double-inlet left ventricle. Am J Cardiol. Jul 15 2005;96(2):291-8. [Medline].

  5. Senzaki H, Masutani S, Kobayashi J, et al. Ventricular afterload and ventricular work in fontan circulation: comparison with normal two-ventricle circulation and single-ventricle circulation with blalock-taussig shunts. Circulation. Jun 18 2002;105(24):2885-92. [Medline].

  6. Cai CL, Liang X, Shi Y, Chu PH, Pfaff SL, Chen J. Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Dev Cell. Dec 2003;5(6):877-89. [Medline].

  7. Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science. May 30 1997;276(5317):1404-7. [Medline].

  8. Srivastava D, Thomas T, Lin Q, et al. Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND. Nat Genet. Jun 1997;16(2):154-60. [Medline].

  9. Svensson EC, Huggins GS, Lin H, et al. A syndrome of tricuspid atresia in mice with a targeted mutation of the gene encoding Fog-2. Nat Genet. Jul 2000;25(3):353-6. [Medline].

  10. Ilagan R, Abu-Issa R, Brown D, Yang YP, Jiao K, Schwartz RJ. Fgf8 is required for anterior heart field development. Development. Jun 2006;133(12):2435-45. [Medline].

  11. von Both I, Silvestri C, Erdemir T, Lickert H, Walls JR, Henkelman RM. Foxh1 is essential for development of the anterior heart field. Dev Cell. Sep 2004;7(3):331-45. [Medline].

  12. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development. Jul 1997;124(13):2659-70. [Medline].

  13. Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, Harriss JV. Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat Genet. May 2002;31(1):25-32. [Medline].

  14. Camenisch TD, Spicer AP, Brehm-Gibson T, Biesterfeldt J, Augustine ML, Calabro A Jr. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest. Aug 2000;106(3):349-60. [Medline].

  15. Zeisberg EM, Ma Q, Juraszek AL, Moses K, Schwartz RJ, Izumo S. Morphogenesis of the right ventricle requires myocardial expression of Gata4. J Clin Invest. Jun 2005;115(6):1522-31. [Medline].

  16. Narkewicz MR, Sondheimer HM, Ziegler JW, et al. Hepatic dysfunction following the Fontan procedure. J Pediatr Gastroenterol Nutr. Mar 2003;36(3):352-7. [Medline].

  17. Chin AJ, Stephens P, Goldmuntz E, Leonard MB. Serum alkaline phosphatase reflects post-Fontan hemodynamics in children. Pediatr Cardiol. Feb 2009;30(2):138-45. [Medline].

  18. Durongpisitkul K, Porter CJ, Cetta F, et al. Predictors of early- and late-onset supraventricular tachyarrhythmias after Fontan operation. Circulation. Sep 15 1998;98(11):1099-107. [Medline].

  19. Jacobs ML, Rychik J, Rome JJ, et al. Early reduction of the volume work of the single ventricle: the hemi-Fontan operation. Ann Thorac Surg. Aug 1996;62(2):456-61; discussion 461-2. [Medline].

  20. Jacobs ML, Norwood WI Jr. Fontan operation: influence of modifications on morbidity and mortality. Ann Thorac Surg. Oct 1994;58(4):945-51; discussion 951-2. [Medline].

  21. Canobbio MM, Mair DD, van der Velde M, Koos BJ. Pregnancy outcomes after the Fontan repair. J Am Coll Cardiol. Sep 1996;28(3):763-7. [Medline].

  22. Camposilvan S, Milanesi O, Stellin G, Pettenazzo A, Zancan L, D'Antiga L. Liver and cardiac function in the long term after Fontan operation. Ann Thorac Surg. Jul 2008;86(1):177-82. [Medline].

  23. Yeh T, Williams WG, McCrindle BW, et al. Equivalent survival following cavopulmonary shunt: with or without the Fontan procedure. Eur J Cardiothorac Surg. Aug 1999;16(2):111-6. [Medline].

  24. Bromberg BI, Schuessler RB, Gandhi SK, et al. A canine model of atrial flutter following the intra-atrial lateral tunnel Fontan operation. J Electrocardiol. 1998;30 Suppl:85-93. [Medline].

  25. Mavroudis C, Deal BJ, Backer CL, Stewart RD, Franklin WH, Tsao S. J. Maxwell Chamberlain Memorial Paper for congenital heart surgery. 111 Fontan conversions with arrhythmia surgery: surgical lessons and outcomes. Ann Thorac Surg. Nov 2007;84(5):1457-65; discussion 1465-6. [Medline].

  26. Petrossian E, Reddy VM, McElhinney DB, et al. Early results of the extracardiac conduit Fontan operation. J Thorac Cardiovasc Surg. Apr 1999;117(4):688-96. [Medline].

  27. Kiesewetter CH, Sheron N, Vettukattill JJ, Hacking N, Stedman B, Millward-Sadler H. Hepatic changes in the failing Fontan circulation. Heart. May 2007;93(5):579-84. [Medline].

  28. Wilson WR, Greer GE, Tobias JD. Cerebral venous thrombosis after the Fontan procedure. J Thorac Cardiovasc Surg. Oct 1998;116(4):661-3. [Medline].

  29. Cohen MI, Rhodes LA, Wernovsky G, Gaynor JW, Spray TL, Rychik J. Atrial pacing: an alternative treatment for protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg. Mar 2001;121(3):582-3. [Medline].

  30. Cheung YF, Tsang HY, Kwok JS. Immunologic profile of patients with protein-losing enteropathy complicating congenital heart disease. Pediatr Cardiol. Nov-Dec 2002;23(6):587-93. [Medline].

  31. Pekkan K, Kitajima HD, de Zelicourt D, et al. Total cavopulmonary connection flow with functional left pulmonary artery stenosis: angioplasty and fenestration in vitro. Circulation. Nov 22 2005;112(21):3264-71. [Medline].

  32. Jacobs ML, Schneider DJ, Pourmoghadam KK, Pizarro C, Norwood WI. Total cavopulmonary connection to one lung. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2004;7:72-9. [Medline].

  33. Troutman WB, Barstow TJ, Galindo AJ, Cooper DM. Abnormal dynamic cardiorespiratory responses to exercise in pediatric patients after Fontan procedure. J Am Coll Cardiol. Mar 1 1998;31(3):668-73. [Medline].

  34. Chang RK, Alejos JC, Atkinson D, et al. Bubble contrast echocardiography in detecting pulmonary arteriovenous shunting in children with univentricular heart after cavopulmonary anastomosis. J Am Coll Cardiol. Jun 1999;33(7):2052-8. [Medline].

  35. Barber BJ, Burch GH, Tripple D, Balaji S. Resolution of plastic bronchitis with atrial pacing in a patient with fontan physiology. Pediatr Cardiol. Jan-Feb 2004;25(1):73-6. [Medline].

  36. Wilson J, Russell J, Williams W, Benson L. Fenestration of the Fontan circuit as treatment for plastic bronchitis. Pediatr Cardiol. Sep-Oct 2005;26(5):717-9. [Medline].

  37. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol. Jan 1 2000;59(1):47-53. [Medline].

  38. Deal BJ, Backer CL, Ward KM, Tsao S, Dechert B, de Freitas A, et al. Medical characteristics and mid-term outcome: 100 consecutive Fontan conversions with arrhythmia surgery. Circulation. 2007;116:II-414.

  39. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med. May 11 2006;354(19):2034-45. [Medline].

  40. Rydberg A, Teien DE, Krus P. Computer simulation of circulation in patient with total cavo-pulmonary connection: inter-relationship of cardiac and vascular pressure, flow, resistance and capacitance. Med Biol Eng Comput. Nov 1997;35(6):722-8. [Medline].

Further Reading

Keywords

single ventricle, single left ventricle, single right ventricle, tricuspid atresia, mitral atresia, double-inlet single ventricle, common-inlet single ventricle, hepatic dysfunction, biliary dysfunction, protein-losing enteropathy, subpulmonary stenosis, aortic arch obstruction, aortic arch hypoplasia, subaortic stenosis, cyanosis, peripheral perfusion, Fontan operation, hypoproteinemia, L-looped single left ventricle, transposition of the great arteries, D-looped single left ventricle, bulboventricular foramen, outlet foramen, bidirectional Glenn operation, hemi-Fontan operation, pulmonary artery distortion, pericardial effusion, pleural effusion, ascites, thrombus, sinus bradycardia, atrial tachyarrhythmias, varices, plastic bronchitis, thrombocytopenia, systemic collaterals, short stature, treatment, diagnosis

Contributor Information and Disclosures

Author

Alvin J Chin, MD, Professor of Pediatrics, Division of Cardiology, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine
Alvin J Chin, MD is a member of the following medical societies: American Association for the Advancement of Science and American Heart Association
Disclosure: Nothing to disclose.

Medical Editor

Juan Carlos Alejos, MD, Clinical Professor, Department of Pediatrics, Division of Cardiology, University of California at Los Angeles
Juan Carlos Alejos, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, American Medical Association, and International Society for Heart and Lung Transplantation
Disclosure: Actelion Honoraria Speaking and teaching

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Ameeta Martin, MD, Clinical Associate Professor, Department of Pediatric Cardiology, University of Nebraska College of Medicine
Ameeta Martin, MD is a member of the following medical societies: American College of Cardiology
Disclosure: Nothing to disclose.

CME Editor

Gilbert Z Herzberg, MD, Assistant Professor, Department of Pediatrics, Section of Pediatric Cardiology, New York Medical College; Consulting Staff, Department of Pediatrics, Sound Shore Medical Center
Gilbert Z Herzberg, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Chief Editor

Stuart Berger, MD, Professor of Pediatrics, Division of Cardiology, Medical College of Wisconsin; Chief of Pediatric Cardiology, Medical Director of Pediatric Heart Transplant Program, Medical Director of The Heart Center, Children's Hospital of Wisconsin
Stuart Berger, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American College of Chest Physicians, American Heart Association, and Society for Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.